Disease-modification under treatment with aflibercept in advanced diabetic retinopathy - A pilot study
Latest Information Update: 26 Nov 2021
Price :
$35 *
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic retinopathy
- Focus Therapeutic Use
- Acronyms DIAMOND
- 26 Nov 2021 Status changed from recruiting to discontinued.
- 10 Oct 2017 New trial record